OBI Pharma Total Assets
OBI Pharma total assets. Based on the latest financial reports, OBI Pharma (4174) holds total assets worth NT$2.69 Billion TWD (≈ $84.75 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 4174 market cap for the company's overall valuation and market capitalisation.
Total Assets of OBI Pharma (2011–2025)
Total assets of OBI Pharma from 2011 to 2025. This chart illustrates how OBI Pharma's total assets have evolved over time, based on quarterly financial data. See 4174 live share price for real-time trading data and today's change.
OBI Pharma - Asset Composition Analysis
OBI Pharma Total Assets Breakdown (December 2025)
OBI Pharma total assets breakdown as of December 2025. OBI Pharma's total assets of NT$2.69 Billion consist of 46.2% current assets and 53.8% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 22.2% |
| Accounts Receivable | NT$10.30 Million | 0.3% |
| Inventory | NT$18.43 Million | 0.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how OBI Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore OBI Pharma short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OBI Pharma's current assets represent 46.2% of total assets in 2025, a decrease from 88.5% in 2011.
- Cash Position: Cash and equivalents constituted 22.2% of total assets in 2025, up from 10.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 9.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 0.5% of total assets.
OBI Pharma Competitors by Total Assets
Key competitors of OBI Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
OBI Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.70 | 6.54 | 28.43 |
| Quick Ratio | 3.62 | 6.46 | 28.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$614.28 Million | NT$1.93 Billion | NT$3.23 Billion |
OBI Pharma - Advanced Valuation Insights
This section examines the relationship between OBI Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.30 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -39.5% |
| Total Assets | NT$3.42 Billion |
| Market Capitalization | $191.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values OBI Pharma's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: OBI Pharma's assets decreased by 39.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for OBI Pharma (2011–2025)
The table below shows the annual total assets of OBI Pharma from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.42 Billion ≈ $107.79 Million |
-39.49% |
| 2024-12-31 | NT$5.65 Billion ≈ $178.12 Million |
+0.89% |
| 2023-12-31 | NT$5.60 Billion ≈ $176.55 Million |
-15.52% |
| 2022-12-31 | NT$6.63 Billion ≈ $209.00 Million |
+47.85% |
| 2021-12-31 | NT$4.49 Billion ≈ $141.36 Million |
-15.98% |
| 2020-12-31 | NT$5.34 Billion ≈ $168.23 Million |
-5.71% |
| 2019-12-31 | NT$5.66 Billion ≈ $178.42 Million |
+20.25% |
| 2018-12-31 | NT$4.71 Billion ≈ $148.37 Million |
-9.26% |
| 2017-12-31 | NT$5.19 Billion ≈ $163.51 Million |
-17.98% |
| 2016-12-31 | NT$6.33 Billion ≈ $199.37 Million |
-13.44% |
| 2015-12-31 | NT$7.31 Billion ≈ $230.34 Million |
+391.30% |
| 2014-12-31 | NT$1.49 Billion ≈ $46.88 Million |
-24.49% |
| 2013-12-31 | NT$1.97 Billion ≈ $62.09 Million |
+125.43% |
| 2012-12-31 | NT$874.17 Million ≈ $27.54 Million |
+67.24% |
| 2011-12-31 | NT$522.72 Million ≈ $16.47 Million |
-- |
About OBI Pharma
OBI Pharma, Inc., a clinical stage oncology company, researches and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin, which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424, which ha… Read more